bobbybobby
MarketsStocksJoin Us

Adaptive Biotechnologies

ADPT

$22.57

-6.66%

Bobby Quantitative Model
Jul 31, 2026

ADPT

Adaptive Biotechnologies

$22.57

-6.66%
Jul 31, 2026
Bobby Quantitative Model

Related headlines

Bullish
Adaptive Biotechnologies (ADPT) Separation Plan Aims to Unlock Value

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

ALNY

Analysis

ADPT price trend

Historical Price
Current Price $22.57
Average Target $22.57
High Target $25.96
Low Target $19.18

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Adaptive Biotechnologies's 12-month outlook, with a consensus price target around $23.86 and implied upside of +5.7% versus the current price.

Average Target

$23.86

0 analysts

Implied Upside

+5.7%

vs. current price

Analyst Count

—

covering this stock

Price Range

$20 - $28

Analyst target range

Drowning in data?

Find the real signal!

Drowning in data?

Find the real signal!

ADPT Technical Analysis

Beta

2.07

2.07x market volatility

Max Drawdown

-39.4%

Largest decline past year

52-Week Range

$10-$25

Price range past year

Annual Return

+120.4%

Cumulative gain past year

PeriodADPT ReturnS&P 500
1m+0.9%+0.2%
3m+58.2%+3.7%
6m+22.0%+8.0%
1y+120.4%+18.2%
ytd+41.9%+9.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Valuation Analysis: Is ADPT Overvalued?

PE

-41.6x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

-89.6x

Enterprise Value Multiple

Related headlines

Bullish
Adaptive Biotechnologies (ADPT) Separation Plan Aims to Unlock Value

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

ALNY

Analysis
Bobby
cs@bobby.ai

Product

  • Bobby AI

Partner

  • RockFlow Platform

Markets

  • Stock Event
  • Macro Event
  • Industry Event

Stocks

  • NVDA
  • AAPL
  • MSFT
  • AMZN
  • GOOG
  • META
  • TSLA
Privacy PolicyTerms of Use

© 2026 Flow AI Limited. All Rights Reserved.

Bobby, the world's first financial AI Agent, is developed by Flow AI, an AI-driven company. Flow AI is dedicated to providing global investors with AI-powered financial services across multiple markets.

Waffo.com Limited (authorised distributor): RM 1903, 19/F Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.